Samuel Backenroth

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of next-generation, targeted medicines for difficult-to-treat medical conditions. Its product candidates are built off of its platform technologies: Vascular Targeting System (VTS), a gene-based technology targeting newly formed blood vessels and Monocyte Targeting Technology (MTT), an antibody-based technology able to specifically inhibit monocyte migration for immune-inflammatory applications. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.

Ohr Pharmaceutical, Inc. engages in the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its product portfolio includes squalamine and SKS sustained release technology. The company was founded by Irach B. Taraporewala in 2008 and is headquartered in New York, NY.

DepYmed , Inc. is a cancer and rare disease therapeutic development company. The company is headquartered in Farmingdale, NY.

Neubase Therapeutics, Inc. develops peptide-nucleic acid antisense oligonucleotide platform. Its platform address repeat expansion disorders, with an initial focus on huntington’s disease and myotonic dystrophy, as well as other dominant genetic disorders. The company was founded by Dietrich A. Stephan and is headquartered in Pittsburgh, PA.

NeuBase Therapeutics, Inc. is a biotechnology company, which engages in the development of drugs for patients with genetic neurological disorders. The firm’s therapies are built on a proprietary platform called PATrOL that encompasses a novel peptide-nucleic acid antisense oligonucleotide technology combined with novel delivery shuttles that overcome many of the hurdles to selective mutation engagement, repeat dosing, and systemic delivery of genetic medicines. The company was founded by Dietrich A. Stephan on August 4, 2009 and is headquartered in Pittsburgh, PA.

Orphion Therapeutics, Inc. develops novel gene therapies for the treatment of genetic disorders. The private company is based in Great Neck, NY. The company was founded by Samuel I. Backenroth. The CEO is Jason Scott Slakter.